WebDoctor Encyclopedia

Childhood Cutaneous lymphomas Lymphomas

Anaplastic large cell lymphoma (ALCL)

Anaplastic large cell lymphoma (ALCL) is an uncommon T-cell non-Hodgkin lymphoma whose cells carry the CD30 protein. It includes ALK-positive and ALK-negative systemic types, a skin-only type and a type linked to breast implants.

Medically reviewed Last reviewed October 17, 2026

What is anaplastic large cell lymphoma?

Anaplastic large cell lymphoma (ALCL) is an uncommon type of non-Hodgkin lymphoma that starts in T cells, a kind of white blood cell that helps the body fight infection. It belongs to the wider group of peripheral T-cell lymphomas (lymphomas of mature T cells).

The name describes how the cancer cells look under the microscope. They are large, and they look “anaplastic”, meaning very abnormal and unlike normal T cells. Every type of ALCL has one feature in common: the cells carry large amounts of a protein called CD30 on their surface.

ALCL is not a single disease. Doctors recognise four types, which differ in who they affect, where they start and how they behave. The most important question for treatment and outlook is whether the cells make a protein called ALK (anaplastic lymphoma kinase).

Some types of ALCL grow quickly and need chemotherapy, while others stay in the skin or around a breast implant and can often be cured with surgery or radiotherapy alone. With modern treatment, many people with ALCL are cured.

1. Types of ALCL

The WHO Classification of Haematolymphoid Tumours, 5th edition (2022) lists the following types of ALCL.

Type Who it usually affects Where it starts Typical behaviour
Systemic ALK-positive ALCL Children, teenagers and adults under 40 Lymph nodes, often with skin, bone or soft tissue Fast-growing, but usually responds well to chemotherapy
Systemic ALK-negative ALCL Mainly adults over 40 Lymph nodes and other organs Fast-growing; outlook varies with the gene changes in the lymphoma
Primary cutaneous ALCL Mainly older adults Skin only Slow-growing; lesions may shrink on their own; rarely spreads
Breast implant-associated ALCL (BIA-ALCL) People with breast implants, mostly textured implants Fluid or scar tissue (capsule) around the implant Usually stays around the implant and is often cured by surgery

Primary cutaneous ALCL belongs to a family called primary cutaneous CD30-positive lymphoproliferative disorders, which also includes the milder condition lymphomatoid papulosis. BIA-ALCL is not breast cancer: it is a lymphoma that grows in the scar tissue around the implant, not in the breast tissue itself.

2. How common is it?

Feature Details
Share of lymphomas A small share of adult non-Hodgkin lymphomas; about 14% of peripheral T-cell lymphomas in a large international study
Children About 10% of childhood non-Hodgkin lymphomas; more than 90% of childhood cases are ALK-positive
ALK-positive ALCL Most common in children and young adults; slightly more common in males
ALK-negative ALCL Usually diagnosed in middle-aged and older adults
Primary cutaneous ALCL Mainly adults over 50; rare in children
BIA-ALCL Rare; the risk is higher with textured than with smooth implants, and the lymphoma usually appears several years after the implant was placed

ALCL is not infectious and cannot be passed on to other people. It is not usually inherited.

3. Causes and risk factors

ALCL develops when a T cell picks up gene changes that make it grow and survive when it should not. These changes are acquired during life; they are not passed on in families.

Gene change Type of ALCL What it does
ALK rearrangement, most often NPM1::ALK from the translocation t(2;5)(p23;q35) ALK-positive ALCL Joins part of the ALK gene to another gene, creating a fusion protein that is always switched on and drives growth through signals such as JAK/STAT3
Other ALK partners (for example TPM3::ALK, ATIC::ALK) ALK-positive ALCL Same effect as NPM1::ALK; found in a minority of cases
DUSP22 rearrangement About 30% of ALK-negative systemic ALCL in one large study; also common in primary cutaneous ALCL Linked with a better outlook in some studies
TP63 rearrangement About 8% of ALK-negative systemic ALCL in the same study Linked with a poorer outlook
JAK1 or STAT3 mutations Some ALK-negative ALCL and BIA-ALCL Switch on the JAK/STAT3 pathway without ALK

Risk factors

  • Textured breast implants. BIA-ALCL is thought to result from long-term inflammation around the textured surface of the implant. The fill (silicone or saline) does not appear to matter.
  • Age. ALK-positive ALCL mainly affects young people, while ALK-negative and skin ALCL mainly affect older adults.
  • No known lifestyle cause. Diet, smoking and alcohol have not been shown to cause ALCL.

4. How does it look?

4.1 On the body

Type Typical appearance
Systemic ALCL Firm, painless swollen lymph nodes in the neck, armpit or groin; sometimes several nodes stuck together
Skin involvement in systemic ALCL Red or purple lumps or patches, sometimes in several areas of the body
Primary cutaneous ALCL One or a few red-brown or purple nodules or tumours, which may break down into an ulcer; most often on the trunk, face, arms or legs
BIA-ALCL A swollen breast caused by fluid around the implant, appearing years after surgery; less often a lump, skin rash or hardening of the capsule

4.2 On scans

Test What it may show
PET-CT Active (“hot”) lymph nodes and organs anywhere in the body; used for staging and to check the response to treatment
CT scan Enlarged lymph nodes in the chest, abdomen and pelvis; masses in the lungs, bone or soft tissue
Breast ultrasound or MRI (BIA-ALCL) A fluid collection (seroma) around the implant, sometimes a mass in the capsule

4.3 Under the microscope

The lymphoma is made of large cells with plenty of cytoplasm. Many contain “hallmark cells”, which have a horseshoe-shaped or kidney-shaped nucleus. The cells often grow inside the lymph node sinuses, the channels that normally carry lymph fluid.

The key tests are special stains. The cells are strongly positive for CD30 in a membrane and dot-like pattern. A stain for ALK separates ALK-positive from ALK-negative disease, and the cells often lose some usual T-cell markers while keeping proteins such as granzyme B, perforin or TIA-1.

Some ALK-positive cases contain mostly small cells or many macrophages (the small cell and lymphohistiocytic patterns). These patterns can be harder to recognise and, in children, have been linked with a higher risk of relapse.

5. Symptoms

Symptoms depend on the type of ALCL and where it grows. Systemic ALCL often causes general symptoms, while skin and breast implant types usually cause only local changes.

Type Common symptoms
Systemic ALK-positive ALCL Painless swollen glands; fever, drenching night sweats and weight loss (“B symptoms”); skin lumps; bone pain; often advanced stage at diagnosis
Systemic ALK-negative ALCL Swollen glands; B symptoms; symptoms from organs such as the bowel, lungs or bones
Primary cutaneous ALCL A skin lump that grows over weeks, may ulcerate or bleed, and sometimes shrinks on its own; people usually feel otherwise well
BIA-ALCL Persistent swelling, pain or a lump in the area of the breast implant, often years after the operation; sometimes a rash or a hardened capsule

Other possible symptoms of systemic ALCL

  • Tiredness, itching or loss of appetite.
  • Cough, chest pain or breathlessness if lymph nodes in the chest or the lungs are involved.
  • Abdominal pain or a swollen tummy if the bowel, liver or spleen is affected.
  • Rarely, a severe inflammatory reaction called haemophagocytic lymphohistiocytosis (HLH), with high fever, low blood counts and an enlarged liver and spleen.

When to see a doctor

  • Swollen glands that last more than 3 weeks or keep growing.
  • Unexplained fevers, night sweats or weight loss.
  • A new skin lump that grows or ulcerates.
  • New swelling, pain or a lump around a breast implant, especially more than a year after surgery.

6. Diagnosis

ALCL can only be diagnosed by examining tissue. The aim is to confirm the diagnosis, find the exact type and see how far the lymphoma has spread.

Test Purpose
Lymph node biopsy (whole node or core needle) Confirms ALCL and allows CD30, ALK and other stains
Skin biopsy For skin lumps; needs a deep enough sample
Fluid aspiration and capsule sampling (BIA-ALCL) Fresh fluid from around the implant is tested with cytology, CD30 staining and flow cytometry
Genetic tests (FISH, sequencing) Look for ALK, DUSP22 and TP63 rearrangements and confirm a clonal T-cell population
Blood tests Full blood count, liver and kidney function, lactate dehydrogenase (LDH), and tests for hepatitis B, hepatitis C and HIV
PET-CT Staging, using the Lugano system (based on Ann Arbor stages I to IV)
Bone marrow biopsy In selected patients with systemic disease
Heart scan (echocardiogram) Before doxorubicin-containing chemotherapy
Brain MRI or lumbar puncture Only if there are nervous system symptoms or a high risk of spread there

People with primary cutaneous ALCL need scans to make sure the lymphoma is truly limited to the skin. Systemic ALCL can also involve the skin, and the two are treated very differently.

7. Treatment

Treatment depends on the type of ALCL, the stage, the person’s age and general health. Care should be led by a lymphoma team, together with dermatologists for skin disease and plastic surgeons for BIA-ALCL.

7.1 Systemic ALCL in adults

For adults with systemic ALCL, the preferred first treatment in current guidelines such as those of the NCCN is brentuximab vedotin plus CHP (often written A+CHP or BV-CHP). This is based on the ECHELON-2 trial in CD30-positive peripheral T-cell lymphoma, in which most patients had systemic ALCL.

Treatment How it works How it is given Main side effects
Brentuximab vedotin + CHP (cyclophosphamide, doxorubicin, prednisone) Brentuximab vedotin is an antibody that finds CD30 and delivers a cell-killing drug into the lymphoma cell; it replaces vincristine in CHOP Into a vein every 3 weeks for 6-8 cycles Low white cell count and infection risk, nerve damage (tingling or numbness), nausea, hair loss, tiredness
CHOP or CHOEP (CHOP with etoposide) Combination chemotherapy Into a vein every 2-3 weeks, usually for 6 cycles Similar to above; mainly used where brentuximab vedotin is not available or suitable
Radiotherapy High-energy X-rays to involved areas Short daily course Tiredness and skin soreness in the treated area
High-dose chemotherapy with autologous stem cell transplant Very strong chemotherapy, followed by return of the patient’s own stem cells In hospital, after first-line chemotherapy Severe low blood counts, infection, mouth sores, fatigue

In ECHELON-2, which included 452 patients, A+CHP improved both progression-free survival and overall survival compared with CHOP. At 5 years, about 70% of patients given A+CHP were alive, compared with about 61% after CHOP.

For ALK-negative systemic ALCL, some centres offer a stem cell transplant in first remission to lower the risk of relapse. For ALK-positive disease in adults, a transplant is usually kept for relapse.

7.2 Systemic ALCL in children and young people

Children are treated in specialist paediatric centres, usually with short, intensive chemotherapy schedules such as the international ALCL99 regimen. Studies by the Children’s Oncology Group (ANHL12P1) have tested adding brentuximab vedotin or the ALK inhibitor crizotinib to this chemotherapy.

Adding crizotinib to ALCL99 chemotherapy caused an unexpectedly high rate of blood clots, so the trial authors do not recommend this combination outside studies. In children, the difference in outlook between ALK-positive and ALK-negative disease seen in adults has not been clearly shown.

7.3 Relapsed or refractory systemic ALCL

Treatment Who it is for Notes
Brentuximab vedotin alone Relapse after previous treatment In a phase II study of 58 patients, 86% responded and 57% had a complete remission
Crizotinib (ALK inhibitor tablet) Relapsed or refractory ALK-positive ALCL Approved in the US in 2021 for children aged 1 year and older and young adults; side effects include low blood counts, eye problems and stomach upset
Other ALK inhibitors (for example alectinib) ALK-positive disease Used in some countries or in trials
Vinblastine Children with relapsed ALCL Effective as a single drug in many children
Salvage chemotherapy then stem cell transplant Relapse that responds to treatment Autologous or allogeneic (donor) transplant
Clinical trials All relapsed patients Newer drugs and cell therapies

7.4 Primary cutaneous ALCL

Situation Usual treatment
One lump or a few lumps close together Surgical removal or local radiotherapy; both usually clear the lesion
Lesion that shrinks on its own Careful observation may be enough
Many lumps in different areas Low-dose methotrexate tablets or injections, or brentuximab vedotin, which was more effective than methotrexate or bexarotene in the ALCANZA trial of CD30-positive skin lymphomas
Spread beyond the skin Treated like systemic ALCL

Multi-drug chemotherapy is rarely needed for skin-only disease. Lesions often come back in the skin, but this does not usually affect life expectancy.

7.5 Breast implant-associated ALCL

The key treatment is a complete surgical removal: taking out the implant together with the whole surrounding scar capsule (total en bloc capsulectomy), with removal of any mass. Most people with disease limited to the fluid and capsule need no further treatment.

Situation Usual treatment
Fluid and capsule only, fully removed Surgery alone, with follow-up
Implant on the other side Often removed as well, because BIA-ALCL can occur on both sides
Remaining disease or tumour that cannot be fully removed Radiotherapy to the area
Spread to lymph nodes or beyond Chemotherapy, usually brentuximab vedotin with CHP, as for systemic ALCL

Removing implants in people who have no symptoms is not recommended by the US Food and Drug Administration. Anyone with new swelling or a lump near an implant should be checked.

7.6 Supportive care

  • Growth factor injections (G-CSF) to help white cell recovery during chemotherapy.
  • Medicines to prevent nausea and some infections.
  • Monitoring of heart function during and after doxorubicin.
  • Fertility advice before treatment, such as sperm or egg storage.
  • Psychological support, help with fatigue and advice on returning to work or school.

8. Outlook

The outlook depends mainly on the type of ALCL. For systemic disease, ALK status, stage, age and the International Prognostic Index (IPI) are the most important factors.

Type Typical outcome
Systemic ALK-positive ALCL (adults) 5-year overall survival of about 70% in an international study of mainly CHOP-treated patients, and higher in some modern series
Systemic ALK-negative ALCL (adults) 5-year overall survival of about 49% in the same study; better than other peripheral T-cell lymphomas
ALK-negative with DUSP22 rearrangement Reported 5-year survival of about 90% in one study, although later studies have been less consistent
ALK-negative with TP63 rearrangement Reported 5-year survival of about 17% in the same study
Children with systemic ALCL Disease-free survival about 60-75% for advanced stages; many children with relapse can still be cured
Primary cutaneous ALCL 5-year overall survival about 90%; skin relapses are common but rarely life-threatening
BIA-ALCL Excellent when the disease is limited to the capsule and fully removed; poorer if there is a mass or spread

These figures come from groups of patients and cannot predict what will happen to one person. Newer treatments such as brentuximab vedotin have improved results since many of these studies were done.

9. Living with ALCL

  • Follow-up visits are usually every 3-6 months for the first 2 years, then less often. Routine scans are not always needed if there are no symptoms.
  • Report new swollen glands, fevers, sweats, weight loss or skin lumps to your team without waiting for the next appointment.
  • After BIA-ALCL surgery, follow-up includes examination of the chest and sometimes ultrasound.
  • Long-term effects of treatment can include nerve damage, heart problems after doxorubicin, reduced fertility and a small risk of second cancers. A healthy lifestyle and regular check-ups help.
  • Ask about vaccinations: inactivated vaccines such as flu and COVID-19 are recommended, while live vaccines are usually avoided for some time after treatment.
  • Support is available from groups such as Lymphoma Action (UK), the Lymphoma Research Foundation and the Leukemia & Lymphoma Society.

10. Frequently asked questions

Question Answer
Is ALCL a type of breast cancer? No. BIA-ALCL is a lymphoma of the immune system that grows around a breast implant, not in the breast tissue
Should I have my breast implants removed? Not if you have no symptoms. See your doctor if you notice swelling, a lump or pain near an implant
Is ALK-positive better than ALK-negative? In adults, ALK-positive systemic ALCL generally has a better outlook. In children, a clear difference has not been shown
Can ALCL be cured? Yes. Many people with systemic ALCL are cured with chemotherapy, and most skin and implant-associated cases are cured with local treatment
Is it inherited? No. The gene changes that cause ALCL develop during life and are not passed on

Resources

  1. Alaggio, R. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms’, Leukemia, 36(7), pp. 1720-1748.
  2. Savage, K.J. et al. (2008) ‘ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project’, Blood, 111(12), pp. 5496-5504.
  3. Parrilla Castellar, E.R. et al. (2014) ‘ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes’, Blood, 124(9), pp. 1473-1480.
  4. Horwitz, S. et al. (2019) ‘Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial’, The Lancet, 393(10168), pp. 229-240.
  5. Horwitz, S. et al. (2022) ‘The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma’, Annals of Oncology, 33(3), pp. 288-298.
  6. Pro, B. et al. (2012) ‘Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study’, Journal of Clinical Oncology, 30(18), pp. 2190-2196.
  7. Mosse, Y.P. et al. (2017) ‘Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a Children’s Oncology Group study’, Journal of Clinical Oncology, 35(28), pp. 3215-3221.
  8. Brugieres, L. et al. (2009) ‘Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group’, Journal of Clinical Oncology, 27(6), pp. 897-903.
  9. Lowe, E.J. et al. (2021) ‘Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1’, Blood, 137(26), pp. 3595-3603.
  10. Lowe, E.J. et al. (2023) ‘Crizotinib in combination with chemotherapy for pediatric patients with ALK+ anaplastic large-cell lymphoma: the results of Children’s Oncology Group trial ANHL12P1’, Journal of Clinical Oncology, 41(11), pp. 2043-2053.
  11. d’Amore, F. et al. (2015) ‘Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 26(Suppl 5), pp. v108-v115.
  12. Willemze, R. et al. (2018) ‘Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 29(Suppl 4), pp. iv30-iv40.
  13. Prince, H.M. et al. (2017) ‘Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial’, The Lancet, 390(10094), pp. 555-566.
  14. Clemens, M.W. et al. (2019) ‘2019 NCCN consensus guidelines on the diagnosis and treatment of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL)’, Aesthetic Surgery Journal, 39(Suppl 1), pp. S3-S13.
  15. National Cancer Institute (2026) Childhood Non-Hodgkin Lymphoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lymphoma/hp/child-nhl-treatment-pdq (Accessed: October 2026).
  16. National Cancer Institute (2026) Non-Hodgkin Lymphoma Treatment (PDQ) – Patient Version. Available at: https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq (Accessed: October 2026).
  17. U.S. Food and Drug Administration (2026) Questions and answers about breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Available at: https://www.fda.gov/medical-devices/breast-implants/breast-implant-associated-anaplastic-large-cell-lymphoma-bia-alcl (Accessed: October 2026).

Prepared by the editorial team, October 2026.